BiotechTube

Lanthanum Carbonate (Fosrenol, BAY77-1931)

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia, Kidney Disease

Trial Timeline

Oct 10, 2013 → Aug 5, 2016

NCT ID
NCT01955876

About Lanthanum Carbonate (Fosrenol, BAY77-1931)

Lanthanum Carbonate (Fosrenol, BAY77-1931) is a pre-clinical stage product being developed by Bayer for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01955876. Target conditions include Hyperphosphatemia, Kidney Disease.

What happened to similar drugs?

2 of 15 similar drugs in Hyperphosphatemia were approved

Approved (2) Terminated (0) Active (13)
✅Tenapanor + Sevelamer CarbonateArdelyxApproved
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
🔄KHK7791 + PlaceboKyowa KirinPhase 3
🔄KHK7791 + PlaceboKyowa KirinPhase 3
🔄KHK7791Kyowa KirinPhase 3
🔄KHK7791Kyowa KirinPhase 3
🔄SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01955876Pre-clinicalCompleted

Competing Products

20 competing products in Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
EOS789 + Placebo + RenvelaChugai PharmaceuticalPhase 1
29
DS-2330b PIB + Placebo + Sevelamer + DS-2330b TabletDaiichi SankyoPhase 1
29
ASP1585 + Placebo + Sevelamer hydrochlorideAstellas PharmaPhase 2
35
ASP1585Astellas PharmaPhase 2
35
the standard-dose group (4 g/day)Kyowa KirinPre-clinical
33
KHK7791 + PlacebpKyowa KirinPhase 2
35
KHK7791Kyowa KirinPhase 2
35
KHK7791 + PlaceboKyowa KirinPhase 3
40
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)Kyowa KirinPre-clinical
33
KHK7791 + PlaceboKyowa KirinPhase 3
40
KHK7791Kyowa KirinPhase 3
40
KHK7791 + PlaceboKyowa KirinPhase 2
35
KHK7791Kyowa KirinPhase 3
40
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HClNovartisPhase 2
35
SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3
40
PA21Kissei PharmaceuticalPhase 3
40
Placebo + Sevelamer Carbonate (GZ419831)SanofiPhase 3
40
Placebo + Sevelamer carbonateSanofiPhase 2
35
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tabletBayerPre-clinical
23
Lanthanum Carbonate (BAY77-1931)BayerPhase 2
32